General
Preferred name
DEFERASIROX
Synonyms
DEFERASIROX ()
ICL 670 ()
CGP-72670 ()
ICL-670 ()
Exjade ()
Deferasirox (ICL-670) ()
CGP-72670, ICL-670 ()
Jadenu ()
ICL-670A ()
Osveral ()
Jadenu sprinkle ()
ICL670A ()
ICL670 ()
P&D ID
PD000116
CAS
201530-41-8
Tags
nuisance
natural product
drug
available
Approved by
EMA
FDA
First approval
2005
Drug Status
investigational
approved
Drug indication
Iron overload disease
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
ROE Deferasirox and metabolites are primarily (84% of the dose) excreted in the feces.; Renal excretion of deferasirox and metabolites is minimal (8% of the administered dose).
Cell lines
6
Organisms
0
Compound Sets
21
Axon Medchem Screening Library
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
JUMP-Target 1 Compound Set
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
NPC Screening Collection
Nuisance compounds in cellular assays
Pandemic Response Box
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
External IDs
40
Properties
(calculated by RDKit )
Molecular Weight
373.11
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
3
Rotatable Bonds
4
Ring Count
4
Aromatic Ring Count
4
cLogP
3.71
TPSA
108.47
Fraction CSP3
0.0
Chiral centers
0.0
Largest ring
6.0
QED
0.5
Structural alerts
1
Chelation
Cell-permeable, Fe
Nuisance compounds in cellular assays
Custom attributes
(extracted from source data)
Target
Iron
CYP3A4
iron chelator
Bacterial
Ferroptosis
Ferroptosis,P450 (e.g. CYP17)
Indication
transfusional hemosiderosis, thalassemia, iron overload
MOA
chelating agent
Pathway
Anti-infection
Apoptosis
Source data